In 2015 DJS Antibodies founded upon a vision of creating the next generation of antibody therapeutics. We developed HEPTAD, a revolutionary platform for antibody discovery, and now use this to create novel therapeutics that will have a meaningful impact on the lives of patients.
to deliver revolutionary
A world where safe, efficacious therapeutics improve the lives of people with chronic inflammatory diseases
What we do
Building a pipeline of unique assets enabled by a world-leading platform for antibody discovery
Having originally come from the sunny shores of Australia, David came to the UK to complete a PhD at the University of Oxford’s Jenner Institute supported by a Rhodes Scholarship. While studying he co-founded and led the Good Lad Initiative, an organisation promoting positive masculinity and gender equality amongst groups of young men. David remains committed to promoting values of equality and diversity throughout DJS and more broadly.
In a past life, David was a competitive kayaker, most often found half way down a waterfall, though now is more likely to be found watching water fall onto his struggling vegetable garden.
As a research associate at DJS, Lara is responsible for performing a wide variety of lab tasks including cell culture, protein expression and purification, cell-based assays, and data analysis.
While not at work she is likely to be doing some sort of exercise (probably running) or be napping alongside one of her dogs.
Joe holds a BSc in Biochemistry from Imperial College London and a PhD in antibody discovery and characterisation from the University of Oxford. After studying Joe worked as an academic on antibody induction and vaccination.
In his spare time he loves playing the guitar, sailing, kicking a football around and growing vegetables.
When he is not helping to navigate the choppy waters of R&D strategy and fund raising, Graeme is most likely to be found on the water casting flies at rising trout, walking the countryside in pursuit of Finnegan the English Setter or learning new woodworking skills in his quest to make order out of chaos.
After graduating from Newcastle University with a BSc (Hons) in Pharmacology and a MRes in Neuroscience, Megan joined DJS Antibodies as a Research Assistant. Working in the lab full-time has allowed her to expand her knowledge, develop her skill set and build up a large repertoire of lab skills and experimental techniques. She currently contributes towards the day-to-day running of the lab, development of new assays and management of our high-throughput antibody screening programmes.
When she is not working, Megan enjoys walking in the countryside with her springer spaniel, cycling, skiing, painting and baking.
Uciane holds a PhD in cancer immunology from Dartmouth College. In addition to working with DJS, Uciane currently represents OSI on the boards of PepGen, Scenic, MiroBio, and Dark Blue Therapeutics.
He was the CEO of F-star in Cambridge, UK (2012-2018), where he built a successful biotech company that initiated two clinical trials in oncology and generated more than €200M in non-dilutive revenue. Previously he was VP Research at ImClone Systems, New York (2010-2012) and before then he was the Chief Scientific Officer and cofounder of Symphogen A/S, Denmark (2000-2009).
After graduating in Medicine in Aarhus Denmark 1992, Dr. Haurum received a D.Phil. in Immunology from the Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, England. Subsequently, he took up positions as Associate Professor at the Danish Cancer Society and completed his medical training.
Cath loves travel, particularly safari trips to southern Africa, sea fishing (including tag and release), whale/dolphin watching (a member of the Whale and Dolphin Conservation Society); wildlife photography; Rugby Union – but just as a spectator!
He's an avid cricket and football fan and spends his spare time getting out on the water.
The latest news and insights from DJS
If you're looking to be surrounded by fantastic people and join an exciting team working on the cutting edge of drug discovery, get in touch!